Brokerages predict that Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) will post earnings of ($0.50) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Kiniksa Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.55) and the highest is ($0.45). The business is expected to issue its next quarterly earnings report on Monday, November 5th.

According to Zacks, analysts expect that Kiniksa Pharmaceuticals will report full-year earnings of ($2.64) per share for the current year, with EPS estimates ranging from ($2.71) to ($2.56). For the next fiscal year, analysts anticipate that the company will post earnings of ($3.04) per share, with EPS estimates ranging from ($3.08) to ($2.99). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Kiniksa Pharmaceuticals.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings data on Monday, August 6th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.53).

Several equities research analysts have recently weighed in on KNSA shares. Goldman Sachs Group started coverage on shares of Kiniksa Pharmaceuticals in a report on Monday, June 18th. They issued a “neutral” rating on the stock. JMP Securities started coverage on shares of Kiniksa Pharmaceuticals in a report on Monday, June 18th. They issued an “outperform” rating and a $33.00 target price on the stock. Wedbush started coverage on shares of Kiniksa Pharmaceuticals in a report on Monday, June 18th. They issued an “outperform” rating and a $31.00 target price on the stock. Finally, JPMorgan Chase & Co. started coverage on shares of Kiniksa Pharmaceuticals in a report on Monday, June 18th. They issued an “overweight” rating and a $29.00 target price on the stock.

In other news, major shareholder Cormorant Asset Management, Lp bought 69,444 shares of the stock in a transaction dated Tuesday, May 29th. The shares were acquired at an average price of $18.00 per share, with a total value of $1,249,992.00. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Bros. Advisors Lp Baker bought 3,000,000 shares of the stock in a transaction dated Tuesday, May 29th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $54,000,000.00. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 3,912,796 shares of company stock worth $71,248,379.

Large investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC bought a new stake in Kiniksa Pharmaceuticals during the 2nd quarter worth about $115,000. BlackRock Inc. bought a new stake in Kiniksa Pharmaceuticals during the 2nd quarter worth about $173,000. Quantitative Systematic Strategies LLC bought a new stake in Kiniksa Pharmaceuticals during the 2nd quarter worth about $348,000. Alps Advisors Inc. bought a new stake in Kiniksa Pharmaceuticals during the 2nd quarter worth about $371,000. Finally, Dean Capital Investments Management LLC bought a new stake in Kiniksa Pharmaceuticals during the 2nd quarter worth about $535,000. 0.42% of the stock is currently owned by hedge funds and other institutional investors.

Shares of KNSA stock traded down $0.42 during mid-day trading on Friday, reaching $15.94. The company’s stock had a trading volume of 226,700 shares, compared to its average volume of 90,161. Kiniksa Pharmaceuticals has a 1-year low of $13.04 and a 1-year high of $24.64.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.

See Also: Outstanding Shares and The Effect on Share Price

Get a free copy of the Zacks research report on Kiniksa Pharmaceuticals (KNSA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.